Abstract
Curcumin is a natural polyphenol product derived from the rhizome of the Curcuma longa. In vivo and in vitro studies have uncovered many important bioactivities of curcumin, such as antioxidant activity, inducing cell apoptosis, inhibiting cell proliferation, anti-cell adhesion and motility, anti-angiogenesis and anti-microbe properties. Based on these functions, curcumin has been used in clinical trials on various inflammatory diseases and cancers. In the future, it will be necessary to focus attention partly on the clinical application of curcumin in neurodegenerative diseases, cardiovascular diseases and diabetes, because many experiments have clarified the potential value of curcumin in these areas. As a diet-derived agent, curcumin has no severe toxicity except for minor gastrointestinal side effects even up to the dosage of 8 grams for 3 months. However, curcumin has a low systemic bioavailability, so it is imperative to improve the bioavailability of curcumin in its clinical application. Many methods, such as adjuvant drug delivery system and structural modification have been demonstrated to have a potential effect.
Keywords: Curcumin, inflammation, cancer, bioavailability, clinical application, polyphenol, Curcuma longa, antioxidant activity, cell apoptosis, anti-angiogenesis
Current Pharmaceutical Design
Title:The Clinical Applications of Curcumin: Current State and the Future
Volume: 19 Issue: 11
Author(s): Xia Fan, Chun Zhang, Dong-bo Liu, Jun Yan and Hua-ping Liang
Affiliation:
Keywords: Curcumin, inflammation, cancer, bioavailability, clinical application, polyphenol, Curcuma longa, antioxidant activity, cell apoptosis, anti-angiogenesis
Abstract: Curcumin is a natural polyphenol product derived from the rhizome of the Curcuma longa. In vivo and in vitro studies have uncovered many important bioactivities of curcumin, such as antioxidant activity, inducing cell apoptosis, inhibiting cell proliferation, anti-cell adhesion and motility, anti-angiogenesis and anti-microbe properties. Based on these functions, curcumin has been used in clinical trials on various inflammatory diseases and cancers. In the future, it will be necessary to focus attention partly on the clinical application of curcumin in neurodegenerative diseases, cardiovascular diseases and diabetes, because many experiments have clarified the potential value of curcumin in these areas. As a diet-derived agent, curcumin has no severe toxicity except for minor gastrointestinal side effects even up to the dosage of 8 grams for 3 months. However, curcumin has a low systemic bioavailability, so it is imperative to improve the bioavailability of curcumin in its clinical application. Many methods, such as adjuvant drug delivery system and structural modification have been demonstrated to have a potential effect.
Export Options
About this article
Cite this article as:
Fan Xia, Zhang Chun, Liu Dong-bo, Yan Jun and Liang Hua-ping, The Clinical Applications of Curcumin: Current State and the Future, Current Pharmaceutical Design 2013; 19 (11) . https://dx.doi.org/10.2174/1381612811319110005
DOI https://dx.doi.org/10.2174/1381612811319110005 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isolation, Synthesis and Biomimetic Reactions of Metalloporphyrinoids in Ionic Liquids
Current Organic Synthesis Back to (non-)Basics: An Update on Neutral and Charge-Balanced Glycosidase Inhibitors
Mini-Reviews in Medicinal Chemistry How Close are We in Achieving Safe, Affordable and Reversible Male Contraceptives?
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice
Current Pediatric Reviews Cutoff Values of D-Dimer and FDP in Plasma for the Diagnosis of Thrombosis
Vascular Disease Prevention (Discontinued) OMICS-Derived Targets for Inflammatory Gut Disorders: Opportunities for the Development of Nutrition Related Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Glycomics and Mass Spectrometry
Current Pharmaceutical Design Monogenic Diabetes: Genetics and Relevance on Diabetes Mellitus Personalized Medicine
Current Diabetes Reviews Liver Fatty Acid Binding Protein (L-FABP) as a Target for the Prevention of High Fat Diet Induced Obesity and Hepatic Steatosis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Delivery Technologies for Protein and Peptide Therapeutics
Current Pharmaceutical Biotechnology Network Propagation Reveals Novel Features Predicting Drug Response of Cancer Cell Lines
Current Bioinformatics Seeking the 5th Base of DNA Using Chromatographic Methods of Analysis
Current Organic Chemistry Overview of Development and Formulation of <sup>177</sup>Lu-DOTA-TATE for PRRT
Current Radiopharmaceuticals Regulators of Stem Cells Proliferation in Tissue Regeneration
Current Stem Cell Research & Therapy Natural Products Derived from the Mediterranean Diet with Antidiabetic Activity: from Insulin Mimetic Hypoglycemic to Nutriepigenetic Modulator Compounds
Current Pharmaceutical Design Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship
Current Drug Metabolism Epigenetic Inheritance of Paternally Expressed Imprinted Genes in the Testes of ICSI Mice
Current Pharmaceutical Design Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Deep Neck Infections: Decisional Algorithm for Patients with Multiple Spaces Involvement
Reviews on Recent Clinical Trials Metabolic Control and Diabetic Retinopathy
Current Diabetes Reviews